Clinical Research Papers:
Pharmacogenomics of platinum-based chemotherapy response in NSCLC: a genotyping study and a pooled analysis
PDF | HTML | Supplementary Files | How to cite
Metrics: PDF 1564 views | HTML 1527 views | ?
Juan Chen1,2, Zhan Wang3, Ting Zou1, Jiajia Cui1, Jiye Yin1,2, Wei Zheng1, Wuzhong Jiang3, Honghao Zhou1,2 and Zhaoqian Liu1,2
1 Department of Clinical Pharmacology, Xiangya Hospital, Central South University, Institute of Clinical Pharmacology, Central South University, Hunan Key Laboratory of Pharmacogenetics, Changsha, P. R. China
2 Hunan Province Cooperation Innovation Center for Molecular Target New Drug Study, Hengyang, P. R. China
3 Department of Oncology, Xiangya Hospital, Central South University, Changsha, P. R. China
Zhaoqian Liu, email:
Keywords: platinum, NSCLC, chemotherapy response, meta-analysis, polymorphism
Received: March 03, 2016 Accepted: May 23, 2016 Published: May 29, 2016
Published data showed inconsistent results about associations of extensively studied polymorphisms with platinum-based chemotherapy response. Our study aimed to provide reliable conclusions of these associations by detecting genotypes of the SNPs in a larger sample size and summarizing a comprehensive pooled analysis. 13 SNPs in 8 genes were genotyped in 1024 NSCLC patients by SequenomMassARRAY. 39 published studies and our study were included in meta-analysis. Patients with GA or GG genotypes of XRCC1 G1196 had better response than AA genotype carriers (Genotyping study: OR = 0.72, 95%CI: 0.53-0.96, P = 0.028; Meta-analysis: OR = 0.74, 95%CI: 0.62-0.89, P = 0.001). Patients carrying CT or TT genotypes of XRCC1 C580T could be more sensitive to platinum-based chemotherapy compared to patients with CC genotype (OR = 0.54, 95%CI: 0.37-0.80, P = 0.002). CC genotype of XRCC3 C18067T carriers showed more resistance to platinum-based chemotherapy when compared to those with CT or TT genotypes (OR = 0.69, 95%CI: 0.52-0.91, P = 0.009). Our study indicated that XRCC1 G1196A/ C580T and XRCC3 C18067T should be paid attention for personalized platinum-based chemotherapy in NSCLC patients.
All site content, except where otherwise noted, is licensed under a Creative Commons Attribution 3.0 License.